BioLineRx (BLRX) Expected to Post Earnings of -$0.07 Per Share

Equities analysts expect BioLineRx (NASDAQ:BLRX) to announce ($0.07) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for BioLineRx’s earnings. BioLineRx posted earnings per share of ($0.08) during the same quarter last year, which suggests a positive year over year growth rate of 12.5%. The company is scheduled to issue its next earnings results before the market opens on Tuesday, May 22nd.

On average, analysts expect that BioLineRx will report full-year earnings of ($0.31) per share for the current fiscal year, with EPS estimates ranging from ($0.34) to ($0.28). For the next year, analysts anticipate that the firm will post earnings of ($0.33) per share, with EPS estimates ranging from ($0.37) to ($0.28). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover BioLineRx.

BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings data on Tuesday, March 6th. The biotechnology company reported ($0.07) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.01).

A number of research firms have commented on BLRX. Zacks Investment Research raised shares of BioLineRx from a “sell” rating to a “hold” rating in a research note on Tuesday, May 8th. ValuEngine raised shares of BioLineRx from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 2nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $4.00 price objective on shares of BioLineRx in a research note on Tuesday, March 6th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $2.85.

BioLineRx opened at $0.92 on Friday, Marketbeat reports. BioLineRx has a twelve month low of $0.85 and a twelve month high of $0.95. The stock has a market cap of $94.55 million, a PE ratio of -3.41 and a beta of 0.53.

A hedge fund recently raised its stake in BioLineRx stock. Renaissance Technologies LLC lifted its stake in BioLineRx (NASDAQ:BLRX) by 60.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 434,700 shares of the biotechnology company’s stock after purchasing an additional 164,500 shares during the quarter. Renaissance Technologies LLC owned 0.41% of BioLineRx worth $474,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 35.32% of the company’s stock.

About BioLineRx

BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.

Get a free copy of the Zacks research report on BioLineRx (BLRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply